. 2021 Dec 29;24(6):948–958. doi: 10.1093/europace/euab298

Table 3.

Comparison of ablation procedure by infarct location (crude)

Procedure variable	Inferior infarct (N = 61), N (%)	Non-inferior infarct (N = 68), N (%)	Sensitivity: anterior infarct (N = 46), N (%)
General anaesthesia used	13 (21.3)	22 (32.4)^a	8 (17.4)^a
Mapping method
Activation mapping	27 (45.0)	23 (33.8)^a	18 (39.1)^a
Entrainment mapping	19 (31.7)	20 (29.4)	20 (43.5)^a
Substrate mapping	54 (90.0)	62 (91.2)	40 (87.0)
Pace mapping	42 (70.0)	50 (73.5)	34 (73.9)
Irrigated catheter used	60 (100.0)	68 (100.0)	46 (100.0)
LV mapped	57 (95.0)	63 (92.7)^a	40 (87.0)^a
RV mapped	15 (25.0)	12 (17.7)^a	9 (19.6)^a
Intracardiac echo used	13 (21.7)	19 (27.9)	10 (21.7)
Mean (SD) fluoroscopy time (min)	31.3 ± 18.9	33.4 ± 23.4	31.8 ± 22.9
Total radiofrequency (RF) time (min)	36.3 ± 21.8	41.3 ± 21.1^a	46.7 ± 23.1^a
Mean (SD) RF applications	37.0 ± 25.0	39.6 ± 26.2	45.5 ± 31.2^a
Inducible VT at baseline	57 (95.0)	59 (86.8)^a	40 (87.0)^a
Distinct monomorphic VTs induced
0	1 (1.7)	4 (6.5)^a	3 (7.0)^a
1	14 (23.7)	13 (21.0)	3 (7.0)^a
2	16 (27.1)	10 (16.1)^a	8 (18.6)^a
≥3	28 (47.5)	41 (56.4)^a	29 (67.4)^a
Induction testing performed post-ablation	48 (80.0)	56 (83.6)^a	36 (78.3)
VT inducible in post-ablation induction testing
Non-inducible arrhythmia	20 (41.7)	33 (56.9)^a	19 (51.4)^a
Clinical VT still inducible	3 (6.3)	1 (1.7)^a	0 (0.0)^a
Non-clinical VT still inducible with ≥300 ms	6 (12.5)	8 (13.8)	5 (13.5)
Non-clinical VT still inducible with <300 ms	19 (39.6)	16 (27.6)^a	13 (35.1)
Acute complications	3 (4.9)	6 (8.8)^a	3 (6.7)^a

LV, left ventricle; RF, radiofrequency; RV, right ventricle; SD, standard deviation; VT, ventricular tachycardia.

SMD >10% are considered unbalanced. SMDs compared noni-inferior and anterior infarct patients to inferior infarct patients.

The per protocol ablation population was used because 129 of 132 patients randomized to ablation underwent the procedure.